CN103153339B - 针对her2表位的单克隆抗体 - Google Patents

针对her2表位的单克隆抗体 Download PDF

Info

Publication number
CN103153339B
CN103153339B CN201180036931.1A CN201180036931A CN103153339B CN 103153339 B CN103153339 B CN 103153339B CN 201180036931 A CN201180036931 A CN 201180036931A CN 103153339 B CN103153339 B CN 103153339B
Authority
CN
China
Prior art keywords
antibody
region
seq
her2
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180036931.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103153339A (zh
Inventor
B.d.戈艾杰
E.N.v.d.布林克
S.海杰
T.里德尔
R.霍埃特
O.巴德斯加尔德
D.萨蒂恩
J.v.d.温克尔
P.帕伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44533416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103153339(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genmab AS filed Critical Genmab AS
Publication of CN103153339A publication Critical patent/CN103153339A/zh
Application granted granted Critical
Publication of CN103153339B publication Critical patent/CN103153339B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180036931.1A 2010-05-27 2011-05-27 针对her2表位的单克隆抗体 Active CN103153339B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34918210P 2010-05-27 2010-05-27
US61/349182 2010-05-27
DKPA201000468 2010-05-27
DKPA201000468 2010-05-27
PCT/EP2011/058772 WO2011147982A2 (en) 2010-05-27 2011-05-27 Monoclonal antibodies against her2 epitope

Publications (2)

Publication Number Publication Date
CN103153339A CN103153339A (zh) 2013-06-12
CN103153339B true CN103153339B (zh) 2021-05-04

Family

ID=44533416

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180036931.1A Active CN103153339B (zh) 2010-05-27 2011-05-27 针对her2表位的单克隆抗体

Country Status (8)

Country Link
US (3) US9714294B2 (OSRAM)
EP (1) EP2575880B1 (OSRAM)
JP (2) JP6082344B2 (OSRAM)
CN (1) CN103153339B (OSRAM)
CA (1) CA2800769C (OSRAM)
IL (2) IL223163A0 (OSRAM)
NZ (1) NZ604007A (OSRAM)
WO (1) WO2011147982A2 (OSRAM)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9272029B2 (en) 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
WO2011147986A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
JP6082344B2 (ja) 2010-05-27 2017-02-15 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
JP6101638B2 (ja) 2011-03-03 2017-03-22 ザイムワークス，インコーポレイテッド 多価ヘテロマルチマー足場設計及び構築物
CN103796677B (zh) * 2011-04-20 2019-08-16 健玛保 针对her2和cd3的双特异性抗体
CA2835203A1 (en) * 2011-05-09 2012-11-15 University Of Virginia Patent Foundation Compositions and methods for treating cancer
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
EP2773671B1 (en) 2011-11-04 2021-09-15 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
EP2806887A4 (en) * 2012-01-26 2015-11-04 Ibc Pharmaceuticals Inc OBJECT TO INTERFERON LAMBDA WITH ANTIBODIES FOR GAINING ANTITUMOR AND ANTIVIRAL EFFECTS
JP6849868B2 (ja) * 2012-05-10 2021-03-31 ザイムワークス，インコーポレイテッド シングルアーム一価抗体構築物およびその用途
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
JP6514103B2 (ja) 2012-07-06 2019-05-15 ゲンマブ ビー．ブイ． 三重変異を有する二量体タンパク質
WO2014012082A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
KR102411491B1 (ko) 2012-11-28 2022-06-22 자임워크스 인코포레이티드 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
KR20220156667A (ko) 2013-01-10 2022-11-25 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
US20160114057A1 (en) * 2013-05-24 2016-04-28 Zyeworks Inc. Modular protein drug conjugate therapeutic
WO2014200891A1 (en) * 2013-06-11 2014-12-18 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH & HUMAN SERVICES Her2-specific monoclonal antibodies and conjugates thereof
WO2015074528A1 (zh) * 2013-11-19 2015-05-28 烟台荣昌生物工程有限公司 抗her2抗体及其缀合物
PL3074424T3 (pl) 2013-11-27 2025-06-09 Zymeworks Bc Inc. Bispecyficzne konstrukty wiążące antygen ukierunkowane na her2
CN112390883A (zh) 2013-12-17 2021-02-23 基因泰克公司 抗cd3抗体及使用方法
MX2016008098A (es) 2013-12-20 2017-01-11 Hoffmann La Roche Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
EP2948184B1 (en) * 2014-01-10 2016-03-23 Synthon Biopharmaceuticals B.V. Duocarmycin adcs showing improved in vivo antitumor activity
US10183996B2 (en) 2014-02-28 2019-01-22 Allakos Inc. Methods and compositions for treating Siglec-8 associated diseases
CN105017421B (zh) * 2014-04-16 2017-12-26 中国人民解放军海军总医院 一种抗her2双特异性抗体及其制备方法与应用
BR112016027888A2 (pt) 2014-05-28 2017-10-24 Zymeworks Inc construto de polipeptídeo de ligação ao antígeno isolado, polinucleotídeo isolado ou um conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do construto, método para tratar um sujeito com uma doença ou distúrbio, método para obter um construto, método para preparar um construto, meio de armazenamento legível por computador, método para produzir um construto de polipeptídeo de ligação com antígeno bi-específico e método para preparar um construto de polipeptídeo de ligação com antígeno isolado
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
CN105367657B (zh) * 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
DK3223848T3 (da) 2014-11-27 2025-03-03 Zymeworks Bc Inc Fremgangsmåder til anvendelse af bispecifikke antigenbindingskonstrukter målrettet her2
CN105985435B (zh) 2015-01-30 2019-10-15 嘉和生物药业有限公司 全人源her2抗体的突变抗体及其编码基因和应用
CN104689335B (zh) * 2015-02-12 2017-12-01 中国科学院上海高等研究院 烯基磺酰胺基作为连接子的抗体药物偶联物及其应用
AU2016262168B2 (en) 2015-05-13 2022-06-23 Zymeworks Bc Inc. Antigen-binding constructs targeting HER2
CA2986713A1 (en) * 2015-05-22 2016-12-01 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a prame peptide
EP3310814B1 (en) 2015-06-16 2023-08-02 F. Hoffmann-La Roche AG Humanized and affinity matured antibodies to fcrh5 and methods of use
CA2991799A1 (en) 2015-07-15 2017-01-19 Zymeworks Inc. Drug-conjugated bi-specific antigen-binding constructs
RS66622B1 (sr) 2015-10-08 2025-04-30 Zymeworks Bc Inc Antigen-vezujući polipeptidni konstrukti koji sadrže kapa i lambda lake lance, i njihove upotrebe
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
ITUA20162242A1 (it) * 2016-04-01 2017-10-01 St Biochimico Italiano Giovanni Lorenzini Spa Un nuovo anticorpo anti-erbb2
EP3241847A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Her-2 binding antibodies
CN110505880A (zh) * 2016-11-04 2019-11-26 基因泰克公司 Her2阳性乳腺癌的治疗
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
CN108610419B (zh) * 2016-12-09 2020-08-18 泰州迈博太科药业有限公司 一种人源化抗her2单克隆抗体
AU2017384900B2 (en) 2016-12-28 2020-12-10 GC Cell Corporation Chimeric antigen receptor and natural killer cells expressing same
BR112019017628A2 (pt) * 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
US11203638B2 (en) 2017-05-05 2021-12-21 Allakos Inc. Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis
TWI757499B (zh) 2017-06-02 2022-03-11 美商輝瑞大藥廠 對flt3具特異性之抗體及其用途
US11517632B2 (en) * 2017-06-20 2022-12-06 Nanomab Technology Limited Anti-Her2 single chain antibody and coding sequence and use thereof
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN111655732B (zh) * 2017-11-14 2023-09-12 Gc细胞治疗 抗her2抗体或其抗原结合片段及包含其的嵌合抗原受体
CA3089287A1 (en) 2018-02-08 2019-08-15 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
EP3752196A4 (en) 2018-02-15 2022-03-23 MacroGenics, Inc. CD3-BINDING DOMAIN VARIANTS AND THEIR USE IN COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES
CN108484772A (zh) * 2018-04-11 2018-09-04 中国人民解放军军事科学院军事医学研究院 抗her2抗原的人源化抗体h5l5及其应用
CN112513074A (zh) 2018-06-22 2021-03-16 健玛保 生产两种或更多种不同抗体的受控混合物的方法
CN110790840A (zh) * 2018-08-01 2020-02-14 三生国健药业（上海）股份有限公司 结合人her2的抗体、其制备方法和用途
EP3849538A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
CN113924116B (zh) * 2019-05-02 2025-11-25 Mab发现股份有限公司 Her2抗体的组合
AU2022273541A1 (en) 2021-05-14 2023-11-30 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
WO2024183623A1 (zh) * 2023-03-03 2024-09-12 盛禾(中国)生物制药有限公司 一种抗her2抗体在制备治疗癌症的药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118635A3 (en) * 2004-06-03 2006-06-15 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
WO2006087637A2 (en) * 2005-02-21 2006-08-24 Hellenic Pasteur Institute Anti her2/neu antibody
WO2006113643A3 (en) * 2005-04-20 2007-09-13 Amgen Fremont Inc High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
ES2274537T5 (es) 1996-03-27 2015-09-14 Genentech, Inc. Anticuerpos ErbB3
KR100628846B1 (ko) 1996-10-18 2006-09-29 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
IL138034A0 (en) 1998-03-27 2001-10-31 Genentech Inc Apo-2 ligand-anti-her-2 antibody synergism
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
AU782325B2 (en) 1999-05-14 2005-07-21 Genentech Inc. Treatment with anti-ErbB2 antibodies
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
KR100850389B1 (ko) 1999-06-25 2008-08-04 제넨테크, 인크. 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법
BR0012196A (pt) 1999-06-25 2002-03-19 Genentech Inc Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
PT1189634E (pt) 1999-06-25 2007-06-06 Genentech Inc Tratamento de cancro da próstata com anticorpos anti-erbb2.
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
EP1282443B1 (en) 2000-05-19 2009-09-02 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
WO2002042468A2 (en) 2000-11-27 2002-05-30 Geron Corporation Glycosyltransferase vectors for treating cancer
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
CN1463270A (zh) 2001-05-31 2003-12-24 梅达莱克斯公司 细胞毒素、其有用的前体药物、连接基团和稳定剂
US7452539B2 (en) 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
WO2003101491A1 (en) 2002-06-03 2003-12-11 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
MXPA05003796A (es) 2002-10-10 2006-02-22 Merck Patent Gmbh Anticuerpos anti-erb-b biespecificos y su uso en terapia de tumor.
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US7309486B1 (en) 2002-11-15 2007-12-18 Mark Zamoyski HER cancer protocols
CA2541360A1 (en) 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
CN1922210A (zh) 2003-12-19 2007-02-28 健泰科生物技术公司 可用作治疗剂的单价抗体片段
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
KR20110050567A (ko) 2004-07-22 2011-05-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JP4958555B2 (ja) 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトＩｇＧ４抗体
WO2006063042A2 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
CA2596133C (en) 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
EP1871424A2 (en) 2005-04-22 2008-01-02 Alza Corporation Immunoliposome composition for targeting to a her2 cell receptor
US8158590B2 (en) 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
JP5346589B2 (ja) 2006-02-02 2013-11-20 シンタルガ・ビーブイ 水溶性ｃｃ−１０６５類似体及びその接合体
EP2975057A1 (en) * 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
PT2511301T (pt) 2006-08-04 2018-03-08 Medimmune Ltd Anticorpos humanos para erbb2
WO2008022746A1 (en) 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-vegf antibody
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
CA2675366A1 (en) 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy
WO2008097229A1 (en) 2007-02-09 2008-08-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Method for spectroscopic quantitation of her-2 in biological samples
PL2132573T3 (pl) 2007-03-02 2014-09-30 Genentech Inc Prognozowanie odpowiedzi na inhibitor dimeryzacji HER oparte na niskiej ekspresji HER3
CA2681790A1 (en) 2007-03-30 2008-10-09 F. Hoffmann-La Roche Ag Composition of labeled and non-labeled monoclonal antibodies
US8715665B2 (en) 2007-04-13 2014-05-06 The General Hospital Corporation Methods for treating cancer resistant to ErbB therapeutics
EP1980626A1 (en) 2007-04-13 2008-10-15 Het Nederlands Kanker Instituut Involvement of lipid kinase, and signal transduction pathway comprising said lipid kinase, in resistance to HER2-targeting therapy
CA2684265A1 (en) 2007-04-19 2008-10-30 Wellstat Biologics Corporation Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment
US20090258005A1 (en) 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
EP2155786B1 (en) 2007-06-06 2015-11-18 F. Hoffmann-La Roche AG Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
DE102007031818A1 (de) 2007-07-07 2009-01-08 Daimler Ag Windschutzeinrichtung
US8680293B2 (en) 2007-08-01 2014-03-25 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
US20110243927A1 (en) 2007-08-24 2011-10-06 University Health Network Methods of inhibiting tumor growth using beta 5 integrin antagonists
EP2190878A1 (en) 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
WO2009055074A2 (en) 2007-10-25 2009-04-30 Wyeth Erbb2 binding proteins and use thereof
GB0722704D0 (en) 2007-11-20 2007-12-27 Cadbury Schweppes Plc Confectionery product
AU2008328779B2 (en) 2007-11-27 2014-06-05 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
CA2707443A1 (en) * 2007-11-30 2009-06-11 Bristol-Myers Squibb Company Conjugates of anti-rg-1 antibodies
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
AU2009212442C1 (en) 2008-02-05 2014-07-17 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
CA2716321A1 (en) 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
JP2010006705A (ja) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Ｈｅｒ２サブセット
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010027981A1 (en) 2008-09-03 2010-03-11 Genentech, Inc. Multispecific antibodies
CN101721700A (zh) 2008-10-15 2010-06-09 哈药集团生物工程有限公司 一种抗人Her2抗体的冻干制剂
WO2010070117A1 (en) 2008-12-18 2010-06-24 Universite Libre De Bruxelles Treatment method by the administration of anti-her2 targeted active compounds to patients with early breast cancer and her2-negative primary tumor
CN101633695B (zh) 2009-04-15 2012-12-12 北京天广实生物技术股份有限公司 基于erbB2蛋白胞外区C-端功能表位特征设计抗erbB2功能抗体
US8446101B2 (en) 2009-07-20 2013-05-21 Gallen Ka Leung Tsui Control switch
US9150663B2 (en) * 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
JP6082344B2 (ja) * 2010-05-27 2017-02-15 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
WO2011147986A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
JP6177231B2 (ja) * 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体
CN103796677B (zh) * 2011-04-20 2019-08-16 健玛保 针对her2和cd3的双特异性抗体
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118635A3 (en) * 2004-06-03 2006-06-15 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
WO2006087637A2 (en) * 2005-02-21 2006-08-24 Hellenic Pasteur Institute Anti her2/neu antibody
WO2006113643A3 (en) * 2005-04-20 2007-09-13 Amgen Fremont Inc High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Discovery of epitopes for targeting the human epidermal growth factor receptor 2(HER2) with antibodies;ROCKBERG J ET AL;《Molecular Oncology》;20090601;第3卷(第3期);对比文件1的摘要以及图1-图7 *
Epitope mapping and structural analysis of an anti-ErbB2 antibody A21:Molecular basis for tumor inhibitory mechanism;SIYI HU ET AL;《PROTEINS:STRUCTURE,FUNCTION,AND BIOINFORMATICS》;20080215;第70卷(第3期);全文 *
ROCKBERG J ET AL.Discovery of epitopes for targeting the human epidermal growth factor receptor 2(HER2) with antibodies.《Molecular Oncology》.2009,第3卷(第3期),对比文件1的摘要以及图1-图7. *

Also Published As

Publication number Publication date
JP6082344B2 (ja) 2017-02-15
IL223163A0 (en) 2013-02-03
IL245274B (en) 2019-08-29
US20180022816A1 (en) 2018-01-25
CN103153339A (zh) 2013-06-12
WO2011147982A3 (en) 2012-03-15
US9714294B2 (en) 2017-07-25
CA2800769C (en) 2021-11-02
US20210122830A1 (en) 2021-04-29
EP2575880B1 (en) 2019-01-16
JP2013534809A (ja) 2013-09-09
US20130171148A1 (en) 2013-07-04
US10793640B2 (en) 2020-10-06
NZ604007A (en) 2015-03-27
WO2011147982A2 (en) 2011-12-01
JP6438442B2 (ja) 2018-12-12
JP2017046694A (ja) 2017-03-09
IL245274A0 (en) 2016-06-30
EP2575880A2 (en) 2013-04-10
CA2800769A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
AU2021261868B2 (en) Monoclonal antibodies against HER2
US20250066506A1 (en) Bispecific antibodies against her2
CN103153339B (zh) 针对her2表位的单克隆抗体
US20140170148A1 (en) Bispecific antibodies against her2
AU2016201799B2 (en) Monoclonal antibodies aganst HER2 epitope
EP2699260B1 (en) Bispecifc antibodies against her2
HK40014440A (en) Monoclonal antibodies against her2
NZ761608A (en) Systems and methods for load balancing across media server instances
NZ761608B2 (en) Systems and methods for merging and compressing compact tori
HK1183882B (en) Monoclonal antibodies against her2
HK1183882A (en) Monoclonal antibodies against her2
HK1183796B (en) Monoclonal antibodies against her2 epitope
HK1183796A (en) Monoclonal antibodies against her2 epitope
HK1195248A (en) Bispecific antibodies against her2
HK1195248B (en) Bispecific antibodies against her2

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: DanMai Val Be

Patentee after: GENMAB A/S

Country or region after: Denmark

Address before: Tanba Goro haro

Patentee before: GENMAB A/S

Country or region before: Denmark

CP03 Change of name, title or address